These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 35454848)

  • 21. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
    Shu C; Li Q
    Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
    Tang L; Zhang M; Liu C
    Front Immunol; 2022; 13():882257. PubMed ID: 35651605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy for Neuro-oncology.
    Majd NK; Dasgupta PR; de Groot JF
    Adv Exp Med Biol; 2021; 1342():233-258. PubMed ID: 34972967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overview of cellular immunotherapy for patients with glioblastoma.
    Vauleon E; Avril T; Collet B; Mosser J; Quillien V
    Clin Dev Immunol; 2010; 2010():. PubMed ID: 20953324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T cell dysfunction in glioblastoma: a barrier and an opportunity for the development of successful immunotherapies.
    Jansen JA; Omuro A; Lucca LE
    Curr Opin Neurol; 2021 Dec; 34(6):827-833. PubMed ID: 34569985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
    Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
    Front Immunol; 2021; 12():637146. PubMed ID: 34025646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic strategies of recurrent glioblastoma and its molecular pathways 'Lock up the beast'.
    El-Khayat SM; Arafat WO
    Ecancermedicalscience; 2021; 15():1176. PubMed ID: 33680090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy.
    Zhai L; Dey M; Lauing KL; Gritsina G; Kaur R; Lukas RV; Nicholas MK; Rademaker AW; Dostal CR; McCusker RH; Raizer JJ; Parsa AT; Bloch O; Wainwright DA
    J Clin Neurosci; 2015 Dec; 22(12):1964-8. PubMed ID: 26279502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New perspective on DNA response pathway (DDR) in glioblastoma, focus on classic biomarkers and emerging roles of ncRNAs.
    Pirlog BO; Ilut S; Pirlog R; Chiroi P; Nutu A; Radutiu DI; Cuc GD; Berindan-Neagoe I; Nabavi SF; Filosa R; Nabavi SM
    Expert Rev Mol Med; 2023 May; 25():e18. PubMed ID: 37154101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging therapies for glioblastoma: current state and future directions.
    Rong L; Li N; Zhang Z
    J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Barriers to overcoming immunotherapy resistance in glioblastoma.
    Gillette JS; Wang EJ; Dowd RS; Toms SA
    Front Med (Lausanne); 2023; 10():1175507. PubMed ID: 37275361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy for Neuro-Oncology.
    Majd N; Dasgupta P; de Groot J
    Adv Exp Med Biol; 2020; 1244():183-203. PubMed ID: 32301015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarkers for glioma immunotherapy: the next generation.
    Sims JS; Ung TH; Neira JA; Canoll P; Bruce JN
    J Neurooncol; 2015 Jul; 123(3):359-72. PubMed ID: 25724916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
    Neagu MR; Reardon DA
    Curr Treat Options Oncol; 2015 Nov; 16(11):54. PubMed ID: 26454859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma.
    Sinnadurai M; McDonald KL
    J Neurooncol; 2017 May; 132(3):359-372. PubMed ID: 28293764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging treatment strategies for glioblastoma multiforme.
    Carlsson SK; Brothers SP; Wahlestedt C
    EMBO Mol Med; 2014 Nov; 6(11):1359-70. PubMed ID: 25312641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using viral vectors to deliver local immunotherapy to glioblastoma.
    Haddad AF; Young JS; Aghi MK
    Neurosurg Focus; 2021 Feb; 50(2):E4. PubMed ID: 33524947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
    Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.